{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:36:31Z","timestamp":1793090191844,"version":"4.5.0"},"reference-count":172,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2022JC023"],"award-info":[{"award-number":["2022JC023"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372855"],"award-info":[{"award-number":["82372855"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072557"],"award-info":[{"award-number":["82072557"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503368"],"award-info":[{"award-number":["82503368"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["22ZR1439200"],"award-info":[{"award-number":["22ZR1439200"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004921","name":"Shanghai Jiao Tong University","doi-asserted-by":"publisher","award":["YG2023ZD04"],"award-info":[{"award-number":["YG2023ZD04"]}],"id":[{"id":"10.13039\/501100004921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M752020"],"award-info":[{"award-number":["2024M752020"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["24ZR1446400"],"award-info":[{"award-number":["24ZR1446400"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2500900"],"award-info":[{"award-number":["2021YFC2500900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105604","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:42:13Z","timestamp":1790178133000},"page":"105604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Recent advances and future challenges of bispecific antibodies in lung cancer"],"prefix":"10.1016","volume":"227","author":[{"given":"Mingyuan","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runsen","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8069-6033","authenticated-orcid":false,"given":"Hecheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.critrevonc.2026.105604_bib1","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105604_bib2","doi-asserted-by":"crossref","first-page":"S1423","DOI":"10.1016\/j.annonc.2022.08.058","article-title":"LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin\/pemetrexed (CP) in treatment-na\u00efve (1L) non-small cell lung cancer (NSCLC): A phase Ib\/II trial","volume":"33","author":"Ahn","year":"2022","journal-title":"Ann. Oncol."},{"issue":"Pt 2","key":"10.1016\/j.critrevonc.2026.105604_bib3","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105604_bib4","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1203498","article-title":"CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors","volume":"5","author":"Bacac","year":"2016","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105604_bib5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","article-title":"Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses","volume":"55","author":"Banta","year":"2022","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105604_bib6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/oncolo\/oyac253","article-title":"Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-\u03b2 and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors","volume":"28","author":"Barlesi","year":"2023","journal-title":"Oncologist"},{"issue":"7_ement","key":"10.1016\/j.critrevonc.2026.105604_bib7","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1158\/1538-7445.AM2023-2633","article-title":"Abstract 2633: Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer","volume":"83","author":"Barnscher","year":"2023","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105604_bib8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jtho.2024.12.029","article-title":"Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A","volume":"20","author":"Besse","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105604_bib9","doi-asserted-by":"crossref","first-page":"S755","DOI":"10.1016\/j.annonc.2023.09.2347","article-title":"1313MO Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB\u2013IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy","volume":"34","author":"Besse","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105604_bib10","doi-asserted-by":"crossref","first-page":"S822","DOI":"10.1016\/j.annonc.2023.09.2477","article-title":"1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced\/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01","volume":"34","author":"Brand\u00e3o","year":"2023","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105604_bib11","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105604_bib12","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105604_bib13","first-page":"276","article-title":"Bispecific antibodies for cancer therapy","volume":"12","author":"Chames","year":"2009","journal-title":"Curr. Opin. Drug. Discov. Devel"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105604_bib14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41416-023-02519-0","article-title":"A phase Ib\/II study of cadonilimab (PD-1\/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer","volume":"130","author":"Chen","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105604_bib15","article-title":"A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1\/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer","volume":"2315330338241249690","author":"Chen","year":"2024","journal-title":"Technol. Cancer Res. Treat."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105604_bib16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/cac2.12359","article-title":"Non-small cell lung cancer in China","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun (Lond)"},{"issue":"10515","key":"10.1016\/j.critrevonc.2026.105604_bib17","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(25)01848-3","article-title":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy for first-line advanced squamous NSCLC (HARMONi-6): a randomised phase 3 trial","volume":"406","author":"Chen","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105604_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jtho.2024.10.013","article-title":"Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as First-Line Treatment for Extensive-Stage SCLC: Results of a Phase 1b Clinical Trial","volume":"20","author":"Chen","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105604_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cac2.12244","article-title":"Anti-PD-L1\/TGF-\u03b2R fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1\/PD-L1 inhibitors in lung cancer","volume":"42","author":"Cheng","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.critrevonc.2026.105604_bib20","doi-asserted-by":"crossref","first-page":"S1062","DOI":"10.1016\/j.annonc.2023.09.1223","article-title":"1992P A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)","volume":"34","author":"Cheng","year":"2023","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105604_bib21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105604_bib22","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1038\/s41591-023-02554-7","article-title":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial","volume":"29","author":"Cho","year":"2023","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105604_bib23","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.jtho.2023.08.018","article-title":"Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial","volume":"18","author":"Cho","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105604_bib24","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105604_bib25","doi-asserted-by":"crossref","first-page":"S1632","DOI":"10.1016\/j.annonc.2024.10.659","article-title":"626MO Tarlatamab in previously treated small cell lung cancer (SCLC): Subgroup analysis of patients from the Asia region in the phase II DeLLphi-301 study","volume":"35","author":"Cho","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105604_bib26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO-24-02835","article-title":"Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2","volume":"44","author":"Cho","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105604_bib27","doi-asserted-by":"crossref","first-page":"8516","DOI":"10.1200\/JCO.2024.42.16_suppl.8516","article-title":"Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2","volume":"42","author":"Cho","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105604_bib28","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1158\/1078-0432.CCR-22-3713","article-title":"FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations","volume":"29","author":"Chon","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105604_bib29","first-page":"A481","article-title":"461\u2005Generation of AZD7789, a novel PD-1 and TIM-3 targeting bispecific antibody, which binds to a differentiated epitope of TIM-3","volume":"10","author":"Clancy-Thompson","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105604_bib30","article-title":"A study of acapatamab (AMG 160) in subjects with non-small-cell lung cancer","volume":"04822298","author":"ClinicalTrials.gov","year":"2026","journal-title":"NCT"},{"key":"10.1016\/j.critrevonc.2026.105604_bib31","article-title":"A clinical study of SI-B001 combined with docetaxel in the treatment of non-small cell lung adenocarcinoma and lung squamous cell carcinoma","author":"ClinicalTrials.gov","year":"2026","journal-title":"NCT05943795"},{"key":"10.1016\/j.critrevonc.2026.105604_bib32","article-title":"Bispecific PSMA\u00d7CD3 antibody CC-1 in patients with squamous cell carcinoma of the lung","author":"ClinicalTrials.gov","year":"2026","journal-title":"NCT04496674"},{"key":"10.1016\/j.critrevonc.2026.105604_bib33","article-title":"SHR-1701 for induction and consolidation therapy in unresectable stage III non-small cell lung cancer","author":"ClinicalTrials.gov","year":"2026","journal-title":"NCT07619911"},{"key":"10.1016\/j.critrevonc.2026.105604_bib34","article-title":"A phase 2 study of zanidatamab in patients with HER2-expressing tumors","author":"ClinicalTrials.gov","year":"2026","journal-title":"NCT06695845"},{"key":"10.1016\/j.critrevonc.2026.105604_bib35","article-title":"A study of obrixtamig (BI 764532) in combination with ezabenlimab in DLL3-positive small cell lung cancer and other neuroendocrine tumours","author":"ClinicalTrials.gov","year":"2026","journal-title":"NCT05879978"},{"key":"10.1016\/j.critrevonc.2026.105604_bib36","article-title":"Safety and clinical activity of nivatrotamab in relapsed\/recurrent metastatic small-cell lung cancer","author":"ClinicalTrials.gov","year":"2026","journal-title":"NCT04750239"},{"key":"10.1016\/j.critrevonc.2026.105604_bib37","article-title":"PM8002 in combination with paclitaxel compared with chemotherapy as second-line treatment in small cell lung cancer","author":"ClinicalTrials.gov","year":"2026","journal-title":"NCT06616532"},{"key":"10.1016\/j.critrevonc.2026.105604_bib38","first-page":"1767","article-title":"Tremelimumab: research and clinical development","volume":"9","author":"Comin-Anduix","year":"2016","journal-title":"Onco Targets Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105604_bib39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105604_bib40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-pathol-011110-130206","article-title":"EGFR mutations and lung cancer","volume":"6","author":"da Cunha Santos","year":"2011","journal-title":"Annu. Rev. Pathol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105604_bib41","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score \u2265 1% in the KEYNOTE-042 Study","volume":"41","author":"de Castro","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105604_bib42","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-20-3725","article-title":"The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer","volume":"27","author":"Deegen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105604_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ddtec.2020.10.002","article-title":"Recent advancements in DVD-Ig based therapeutic development","volume":"34","author":"Dong","year":"2019","journal-title":"Drug. Discov. Today Technol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105604_bib44","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-20-1445","article-title":"Design and Efficacy of a Monovalent Bispecific PD-1\/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1(+) Activated T Cells","volume":"11","author":"Dovedi","year":"2021","journal-title":"Cancer Discov."},{"issue":"29","key":"10.1016\/j.critrevonc.2026.105604_bib45","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.24.00553","article-title":"Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update","volume":"42","author":"Dowlati","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"5827","key":"10.1016\/j.critrevonc.2026.105604_bib46","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105604_bib47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.2026.7745","article-title":"Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial","volume":"336","author":"Fang","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2026.105604_bib48","doi-asserted-by":"crossref","first-page":"S995","DOI":"10.1016\/j.annonc.2021.08.1880","article-title":"1278P SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-\u03b2, as first-line therapy for PD-L1+ advanced\/metastatic NSCLC: Data from a clinical expansion cohort of a phase I study","volume":"32","author":"Feng","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105604_bib49","doi-asserted-by":"crossref","first-page":"S1667","DOI":"10.1016\/j.annonc.2023.10.590","article-title":"511MO A phase I study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-\u03b2, in patients with advanced non-small cell lung cancer (NSCLC)","volume":"34","author":"Feng","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105604_bib50","author":"Food","year":"2026","journal-title":"FDA Grants Tradit. Approv. Tarl. -dlle extensive-Stage small-Cell. lung Cancer Novemb. 19 2025. Access. August 18"},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105604_bib51","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105604_bib52","article-title":"A phase 1a\/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors","volume":"4","author":"Frentzas","year":"2023","journal-title":"Cell. Rep. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105604_bib53","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nrd4478","article-title":"Bispecific antibodies rise again","volume":"13","author":"Garber","year":"2014","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105604_bib54","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.ccell.2018.04.003","article-title":"Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade","volume":"33","author":"Geuijen","year":"2018","journal-title":"Cancer Cell."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105604_bib55","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies \u2014 BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105604_bib56","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2023.41.16_suppl.3621","article-title":"Efficacy and safety of KN026 in combination with KN046 in patients with locally advanced unresectable or metastatic HER2-positive other solid tumors","volume":"41","author":"Gong","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105604_bib57","article-title":"Non-small-cell lung cancer","volume":"1","author":"Gridelli","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105604_bib58","doi-asserted-by":"crossref","first-page":"TPS8604","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8604","volume":"41","author":"Guisier","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105604_bib59","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.imbio.2008.11.014","article-title":"Mode of cytotoxic action of T cell-engaging BiTE antibody MT110","volume":"214","author":"Haas","year":"2009","journal-title":"Immunobiology"},{"issue":"4_ement","key":"10.1016\/j.critrevonc.2026.105604_bib60","doi-asserted-by":"crossref","first-page":"P6-17-13","DOI":"10.1158\/1538-7445.SABCS18-P6-17-13","article-title":"Abstract P6-17-13: ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers","volume":"79","author":"Hamblett","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105604_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90096-8","article-title":"A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells","volume":"11","author":"Harris","year":"2021","journal-title":"Sci. Rep."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105604_bib62","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10, ement","key":"10.1016\/j.critrevonc.2026.105604_bib63","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jtho.2024.09.061","article-title":"OA11.03 Efficacy and Safety of Rilvegostomig, an Anti-PD-1\/TIGIT Bispecific, for CPI-na\u00efve Metastatic NSCLC with PD-L1 1-49% or \u226550%","volume":"19","author":"Hiltermann","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105604_bib64","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105604_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116669","article-title":"Preclinical imaging evaluation of a bispecific antibody targeting hPD1\/CTLA4 using humanized mice","volume":"175","author":"Hou","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105604_bib66","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1007\/s12325-025-03136-4","article-title":"Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial","volume":"42","author":"Hummel","year":"2025","journal-title":"Adv. Ther."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105604_bib67","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab Plus Chemotherapy in Non\u2013Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial","volume":"332","author":"Investigators","year":"2024","journal-title":"JAMA"},{"issue":"16_ement","key":"10.1016\/j.critrevonc.2026.105604_bib68","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1158\/1538-7445.AM2020-3022","article-title":"Abstract 3022: Using translational tumor growth inhibition modeling approach and population PK analysis to predict efficacious doses for KN026, a HER2 bispecific antibody","volume":"80","author":"Ji","year":"2020","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105604_bib69","article-title":"Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD-L1 and CTLA-4","volume":"8","author":"Jiang","year":"2021","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105604_bib70","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CCO.0000000000001206","article-title":"The evolving landscape of bispecific antibodies in lung cancer","volume":"38","author":"Jin","year":"2026","journal-title":"Curr. Opin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105604_bib71","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study","volume":"41","author":"Johnson","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105604_bib72","article-title":"Bispecific Antibodies in Lung Cancer: A State-of-the-Art Review","volume":"16","author":"Khosla","year":"2023","journal-title":"Pharm. (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105604_bib73","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/1078-0432.CCR-15-1535","article-title":"Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas","volume":"23","author":"Kim","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105604_bib74","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.critrevonc.2026.105604_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"issue":"14_ement","key":"10.1016\/j.critrevonc.2026.105604_bib76","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1158\/1538-7445.AM2016-3217","article-title":"Abstract 3217: MGD013, a bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART\u00ae) protein with T-cell immunomodulatory activity for cancer treatment","volume":"76","author":"LaMotte-Mohs","year":"2016","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105604_bib77","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004122","article-title":"Colocalized targeting of TGF-\u03b2 and PD-L1 by bintrafusp alfa elicits distinct antitumor responses","volume":"10","author":"Lan","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"424","key":"10.1016\/j.critrevonc.2026.105604_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5488","article-title":"Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2","volume":"10","author":"Lan","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105604_bib79","first-page":"A489","article-title":"469\u2005Preclinical studies support clinical development of AZD2936, a monovalent bispecific humanized antibody targeting PD-1 and TIGIT","volume":"10","author":"Lee","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105604_bib80","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1158\/1078-0432.CCR-15-2622","article-title":"Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing","volume":"22","author":"Lehmann","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"30","key":"10.1016\/j.critrevonc.2026.105604_bib81","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.24.01001","article-title":"Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study","volume":"42","author":"Leighl","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"8_","key":"10.1016\/j.critrevonc.2026.105604_bib82","doi-asserted-by":"crossref","first-page":"CT057","DOI":"10.1158\/1538-7445.AM2026-CT057","article-title":"Abstract CT057: Preliminary results from the first-in-human study of MK-2010, a PD-1\u00d7VEGF bispecific antibody","volume":"86","author":"Li","year":"2026","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105604_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-079132","article-title":"Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1\/PD-L1 therapy: a phase 2 multicentre study","volume":"14","author":"Lin","year":"2024","journal-title":"BMJ Open."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105604_bib84","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2236265","article-title":"Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition","volume":"15","author":"Lipinski","year":"2023","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105604_bib85","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S1556-0864(23)00257-5","article-title":"30 Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC","volume":"18","author":"Lopez","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"10548","key":"10.1016\/j.critrevonc.2026.105604_bib86","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/S0140-6736(26)00966-9","article-title":"Overall survival with ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in HARMONi-6: prespecified interim analysis","volume":"407","author":"Lu","year":"2026","journal-title":"Lancet"},{"issue":"36_","key":"10.1016\/j.critrevonc.2026.105604_bib87","article-title":"Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II\/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study","volume":"41","author":"Lu","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105604_bib88","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"issue":"15_","key":"10.1016\/j.critrevonc.2026.105604_bib89","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2020.38.15_suppl.3004","article-title":"A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms","volume":"38","author":"Luke","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105604_bib90","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol."},{"issue":"8_","key":"10.1016\/j.critrevonc.2026.105604_bib91","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1158\/1538-7445.AM2025-6061","article-title":"Abstract 6061: Dual PD-L1 blockade and VEGF-A neutralization with the bispecific antibody BNT327\/PM8002 shows potent antitumor activity in preclinical models","volume":"85","author":"Miao","year":"2025","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105604_bib92","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cllc.2026.02.001","article-title":"Subcutaneous delivery of amivantamab in advanced solid malignancies: results from the phase Ib PALOMA study","volume":"27","author":"Minchom","year":"2026","journal-title":"Clin. Lung Cancer"},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105604_bib93","doi-asserted-by":"crossref","first-page":"9126","DOI":"10.1200\/JCO.2023.41.16_suppl.9126","article-title":"Subcutaneous amivantamab in patients with advanced solid malignancies: the PALOMA study\u2014updated safety and identification of the recommended phase 2 dose","volume":"41","author":"Minchom","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105604_bib94","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/1535-7163.MCT-23-0524","article-title":"HPN328, a trispecific T cell-activating protein construct targeting DLL3-expressing solid tumors","volume":"23","author":"Molloy","year":"2024","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105604_bib95","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105604_bib96","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2025. Accessed May 27, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf."},{"key":"10.1016\/j.critrevonc.2026.105604_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100641","article-title":"Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET","volume":"296","author":"Neijssen","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105604_bib98","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1556-0864(25)00317-X","article-title":"122TiP: TROPION-Lung10: Phase III study of datopotamab deruxtecan (Dato-DXd) + rilvegostomig in non-squamous (NSQ) advanced\/metastatic (a\/m) non-small cell lung cancer (NSCLC) with high PD-L1 expression and without actionable genomic alterations (AGAs)","volume":"20","author":"Newsom-Davis","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105604_bib99","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study","volume":"41","author":"Novello","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105604_bib100","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105604_bib101","author":"Oncology","year":"2026","journal-title":"Volunt. Announc. Progress. Clin. Trials core Product. KN046 (ENREACH-LUNG-01). Sept. 8 2024. Access. August 19"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105604_bib102","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity","volume":"15","author":"Pang","year":"2023","journal-title":"MAbs"},{"issue":"30","key":"10.1016\/j.critrevonc.2026.105604_bib103","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105604_bib104","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/S1556-0864(25)00328-4","article-title":"133TiP: A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7","volume":"20","author":"Passaro","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105604_bib105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105604_bib106","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S1470-2045(25)00480-2","article-title":"Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study","volume":"26","author":"Paulson","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105604_bib107","doi-asserted-by":"crossref","first-page":"S1664","DOI":"10.1016\/j.annonc.2023.10.587","article-title":"508MO Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study","volume":"34","author":"Paz-Ares","year":"2023","journal-title":"Ann. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105604_bib108","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105604_bib109","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."},{"issue":"10212","key":"10.1016\/j.critrevonc.2026.105604_bib110","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105604_bib111","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jtho.2020.03.003","article-title":"Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-\u03b2 and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105604_bib112","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","article-title":"First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial","volume":"17","author":"Paz-Ares","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105604_bib113","doi-asserted-by":"crossref","first-page":"8513","DOI":"10.1200\/JCO.2026.44.16_suppl.8513","article-title":"Phase 2 data from ROSETTA Lung-02, a global randomized phase 2\/3 trial of pumitamig (PD-L1 \u00d7 VEGF-A bsAb) plus chemotherapy in first-line NSCLC","volume":"44","author":"Peters","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105604_bib114","doi-asserted-by":"crossref","first-page":"S1244","DOI":"10.1016\/j.annonc.2024.08.2296","article-title":"LBA54 Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2","volume":"35","author":"Popat","year":"2024","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105604_bib115","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41587-022-01510-z","article-title":"A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy","volume":"41","author":"Quijano-Rubio","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105604_bib116","first-page":"TPS8603","article-title":"Phase 2 study of tarlatamab, a DLL3-targeting, half-life-extended, bispecific T-cell engager (HLE BiTE)immuno-oncology therapy, in relapsed\/refractory small cell lung cancer (SCLC). J","volume":"40","author":"Ramalingam","year":"2022","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105604_bib117","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.annonc.2022.02.186","article-title":"155TiP Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE\u00ae) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC)","volume":"33","author":"Ramalingam","year":"2022","journal-title":"Ann. Oncol."},{"issue":"12_ement","key":"10.1016\/j.critrevonc.2026.105604_bib118","doi-asserted-by":"crossref","first-page":"C030","DOI":"10.1158\/1535-7163.TARG-23-C030","article-title":"Abstract C030: HARMONi-3: A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer","volume":"22","author":"Riess","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105604_bib119","doi-asserted-by":"crossref","first-page":"9050","DOI":"10.1200\/JCO.2023.41.16_suppl.9050","volume":"41","author":"Rohrberg","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105604_bib120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105604_bib121","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105604_bib122","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting TIM-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105604_bib123","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105604_bib124","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/2159-8290.CD-21-1119","article-title":"Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements","volume":"12","author":"Schram","year":"2022","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105604_bib125","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41591-024-02965-0","article-title":"Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial","volume":"30","author":"Schuler","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105604_bib126","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1038\/s41467-024-48479-8","article-title":"CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials","volume":"15","author":"Segal","year":"2024","journal-title":"Nat. Commun."},{"issue":"7900","key":"10.1016\/j.critrevonc.2026.105604_bib127","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","article-title":"A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells","volume":"603","author":"Seung","year":"2022","journal-title":"Nature"},{"issue":"15_","key":"10.1016\/j.critrevonc.2026.105604_bib128","doi-asserted-by":"crossref","first-page":"9055","DOI":"10.1200\/JCO.2021.39.15_suppl.9055","article-title":"SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-\u03b2, for advanced NSCLC with EGFR mutations: Data from a multicenter phase 1 study","volume":"39","author":"Shi","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105604_bib129","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23105686","article-title":"Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy","volume":"23","author":"Shin","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105604_bib130","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105604_bib131","series-title":"Epidemiology, and End Results Program. Cancer Stat Facts: Lung and Bronchus Cancer","author":"Surveillance","year":"2026"},{"key":"10.1016\/j.critrevonc.2026.105604_bib132","author":"Therapeutics","year":"2026","journal-title":"Inc. Ivonescimab Chemother. Demonstr. Stat. Signif. Clin. Mean. Improv. Progress. -Free. Surviv. Patients EGFR-Mutant Non-small Cell. lung Cancer EGFR-TKI Ther. Glob. Harmon. Study May 30 2025. Access. August 10"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105604_bib133","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40259-022-00521-1","article-title":"Tumor in the Crossfire: Inhibiting TGF-\u03b2 to Enhance Cancer Immunotherapy","volume":"36","author":"Tschernia","year":"2022","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105604_bib134","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative Pembrolizumab for Early-Stage Non\u2013Small-Cell Lung Cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10, ement","key":"10.1016\/j.critrevonc.2026.105604_bib135","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jtho.2024.09.025","article-title":"OA01.06 A Phase II Study of Perioperative Ivonescimab Alone or Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer","volume":"19","author":"Wang","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"10, ement","key":"10.1016\/j.critrevonc.2026.105604_bib136","doi-asserted-by":"crossref","first-page":"S540","DOI":"10.1016\/j.jtho.2024.09.1000","article-title":"EP.07C.02 Perioperative Cadonilimab and Chemotherapy in Stage II-IIIA Non-Small-Cell Lung Cancer: Preliminary Results from a Phase II Study","volume":"19","author":"Wang","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105604_bib137","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1038\/s41467-026-74241-3","article-title":"Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trial","volume":"17","author":"Wang","year":"2026","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105604_bib138","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jtho.2023.10.014","article-title":"A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC","volume":"19","author":"Wang","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105604_bib139","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-019-0759-9","article-title":"MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer","volume":"12","author":"Wang","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105604_bib140","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40259-026-00775-z","article-title":"Clinical Benefit and Global Regulation of Bispecific Antibody Drugs: A Cross-sectional Analysis","volume":"40","author":"Wang","year":"2026","journal-title":"BioDrugs"},{"issue":"13_ement","key":"10.1016\/j.critrevonc.2026.105604_bib141","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/1538-7445.AM2017-31","article-title":"Abstract 31: Preclinical development of a novel biparatopic HER2 antibody with activity in low to high HER2 expressing cancers","volume":"77","author":"Weisser","year":"2017","journal-title":"Cancer Res."},{"issue":"27","key":"10.1016\/j.critrevonc.2026.105604_bib142","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO-25-00363","article-title":"Obrixtamig (BI 764532), a DLL3-targeting T-cell engager, in DLL3-positive neuroendocrine carcinomas: a phase I study","volume":"43","author":"Wermke","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105604_bib143","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105604_bib144","doi-asserted-by":"crossref","first-page":"8533","DOI":"10.1200\/JCO.2024.42.16_suppl.8533","article-title":"A phase Ib\/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC","volume":"42","author":"Wu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105604_bib145","doi-asserted-by":"crossref","first-page":"S1006","DOI":"10.1016\/j.annonc.2021.08.1902","article-title":"1300P A phase Ib\/II trial of AK104 (PD-1\/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC","volume":"32","author":"Wu","year":"2021","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105604_bib146","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105604_bib147","doi-asserted-by":"crossref","first-page":"S804","DOI":"10.1016\/j.annonc.2024.08.1312","article-title":"1255MO A phase II safety and efficacy study of PM8002\/BNT327 in combination with chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC)","volume":"35","author":"Wu","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105604_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.05.024","article-title":"Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study","volume":"190","author":"Xiong","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"10481","key":"10.1016\/j.critrevonc.2026.105604_bib149","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105604_bib150","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1016\/j.xphs.2020.06.015","article-title":"Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI-B001, an EGFR\/HER3 Bi-specific Monoclonal Antibody","volume":"109","author":"Xue","year":"2020","journal-title":"J. Pharm. Sci."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105604_bib151","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1158\/1078-0432.CCR-25-0206","article-title":"Izalontamab (SI-B001), a Novel EGFR\u00d7HER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I\/Ib Study","volume":"31","author":"Xue","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105604_bib152","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105604_bib153","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/pbc.24237","article-title":"Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets","volume":"59","author":"Yankelevich","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105604_bib154","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.cell.2022.02.025","article-title":"Facile discovery of surrogate cytokine agonists","volume":"185","author":"Yen","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105604_bib155","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1483454","article-title":"Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy","volume":"14","author":"Yin","year":"2024","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105604_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188707","article-title":"Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunities","volume":"1877","author":"Zhang","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105604_bib157","doi-asserted-by":"crossref","first-page":"9087","DOI":"10.1200\/JCO.2023.41.16_suppl.9087","article-title":"Phase II results of ivonescimab (AK112\/SMT112), a novel PD-1\/VEGF bispecific, in combination with chemotherapy for first-line treatment of advanced or metastatic non-small-cell lung cancer without actionable EGFR\/ALK alterations","volume":"41","author":"Zhang","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"15_","key":"10.1016\/j.critrevonc.2026.105604_bib158","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/JCO.2020.38.15_suppl.3020","article-title":"The preliminary efficacy and safety data of KN046 in patients failed on prior immune checkpoint inhibitors therapy","volume":"38","author":"Zhao","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105604_bib159","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241270589","article-title":"Advances in Predictive Biomarkers for Anti-Angiogenic Therapy in Non-Small Cell Lung Cancer","volume":"31","author":"Zhao","year":"2024","journal-title":"Cancer Control."},{"key":"10.1016\/j.critrevonc.2026.105604_bib160","doi-asserted-by":"crossref","first-page":"S824","DOI":"10.1016\/j.annonc.2023.09.2480","article-title":"1449P The preliminary data from a single-arm, open-label, multicenter phase II clinical trial: KN046 combined with axitinib as first-line (1L) treatment for NSCLC","volume":"34","author":"Zhao","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105604_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107355","article-title":"A multicenter, open-label phase Ib\/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non\u2013small-cell lung cancer (AK104-202 study)","volume":"184","author":"Zhao","year":"2023","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105604_bib162","article-title":"KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial","volume":"5","author":"Zhao","year":"2024","journal-title":"Cell. Rep. Med."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105604_bib163","doi-asserted-by":"crossref","first-page":"9025","DOI":"10.1200\/JCO.2023.41.16_suppl.9025","article-title":"SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR\/ALK wild-type non-small cell lung cancer: a phase II, multicenter, open-label study","volume":"41","author":"Zhao","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105604_bib164","first-page":"A1316","article-title":"1194\u2005Mechanism of action of ivonescimab (AK112\/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects","volume":"11","author":"Zhong","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105604_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111722","article-title":"Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effects","volume":"28","author":"Zhong","year":"2025","journal-title":"iScience"},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105604_bib166","first-page":"8514","article-title":"Updated results from a phase 2 trial of SSGJ-707 (PF-08634404), a PD-1\/VEGF bispecific antibody, as monotherapy in patients with advanced NSCLC","volume":"44","author":"Zhou","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105604_bib167","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105604_bib168","doi-asserted-by":"crossref","first-page":"S767","DOI":"10.1016\/j.annonc.2023.09.2363","article-title":"1330P Updated results of the efficacy and safety of KN046 (a bispecific anti-PD-L1\/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed prior EGFR-TKI(s)","volume":"34","author":"Zhou","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105604_bib169","doi-asserted-by":"crossref","first-page":"S829","DOI":"10.1016\/j.annonc.2023.09.2490","article-title":"1459P Preliminary efficacy and safety of KN046 (a bispecific anti-PD-L1\/CTLA-4) in patients with metastatic non-small cell lung cancer who previously treated with immune checkpoint inhibitor(s)","volume":"34","author":"Zhou","year":"2023","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105604_bib170","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.ccell.2024.05.024","article-title":"Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105604_bib171","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.15748","article-title":"Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis","volume":"3","author":"Zhou","year":"2020","journal-title":"JAMA Netw. Open."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105604_bib172","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"VK. TIM-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Zhu","year":"2017","journal-title":"Immunol. Rev."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:48:11Z","timestamp":1793087291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":172,"alternative-id":["S1040842826004919"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105604","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances and future challenges of bispecific antibodies in lung cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105604","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105604"}}